Press Release

Harbour BioMed Enters into a License and Collaboration Agreement with Moderna

November 11, 2022

Harbour BioMed
on WeChat

Back to list

Harbour BioMed Enters into a License and Collaboration Agreement with Moderna

November 11, 2022

Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 11, 2022


Harbour BioMed (the “Company”, HKEX: 02142) today announced that Nona Biosciences, a subsidiary wholly owned by the Company, had entered into a license and collaboration agreement with ModernaTX, Inc. (NASDAQ: MRNA), a global biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The strategic collaboration will focus on discovering and developing nucleic acid-based immunotherapies for select oncology targets using the Company’s proprietary heavy chain only antibody discovery platform (HCAb). [HKEX Disclosure]


Upon the execution of the agreement and subject to terms and conditions thereof, Moderna will be granted an exclusive sub-licensable license to exploit a panel of sequences against multiple targets, derived from the Company’s HCAb platform, to develop products using nucleic acids. Moderna will assume full responsibility for all upcoming development, manufacturing, regulatory, and commercialization activities. Moderna would also be granted an option to obtain an exclusive sub-licensable license to exploit sequences against additional targets. Pursuant to the agreement, Nona Biosciences shall receive an upfront payment, and potential milestone payments based on pending achievement of certain regulatory, development, and sales milestones, and tiered royalties.


 "We are very pleased and proud to collaborate with Moderna, a pioneering industry leader in the field of mRNA technology," said Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. “This agreement marks a significant milestone in the Company’s business development, validating the potential of the Company’s technology platforms and innovation capabilities. Following a series of business achievements delivered on a global basis, we will continue to open up our technology platforms and talent and experience to innovators to empower global biotherapeutic innovation.”


About HCAb


HCAb's patented technology generates novel "heavy chain only" antibodies, which are about half the size of a typical IgG. These antibodies carry IgG-like PK properties and Fc-domain functions without the need for additional engineering or humanization. Lack of light chain also minimizes the issue of light chain mispairing and heterodimerization. These characteristics enable the development of products with attributes not achievable by conventional antibody platforms. In addition, HCAb-derived multiple novel therapeutic antibody modalities, including single-domain antibodies, bi-, and multi-specifics, antibody-drug conjugates, CAR-Ts, or VH domain-derived diagnostic or therapeutic products, are also achievable using this platform.


About Nona Biosciences


Nona Biosciences (a subsidiary wholly owned by Harbour BioMed) is a global biotechnology company committed to providing I to ITM (Idea to IND) total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging the advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. 


About Harbour BioMed


Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.
The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, and HBICE® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies.  The values of the antibody discovery platforms have been well validated by more than 50 industry and academic partners.

Media Contact:

Harbour BioMed Public Relations